tert-Butyl (2-(2-chloropyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)carbamate

Catalog No. :
ACUJJF772
CAS No. :
1798792-44-5
Molecular Formula :
C20H24ClN3O2
Molecular Weight :
373.88

IUPAC Name:tert-butyl (2-(2-chloropyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)carbamate

tert-Butyl (2-(2-chloropyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)carbamate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$780.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl (2-(2-chloropyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)carbamate
IUPAC Nametert-butyl (2-(2-chloropyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)carbamate
MDL No.MFCD28388095
Molecular FormulaC20H24ClN3O2
Molecular Weight373.88
SMILESO=C(OC(C)(C)C)NC1CCCCC2=CC(C3=NC(Cl)=NC=C3)=CC=C21
InChI KeyLPPVKASAUROTBP-UHFFFAOYSA-N
Synonymtert-butyl N-[2-(2-chloropyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl]carbamate;Carbamic acid, N-[2-(2-chloro-4-pyrimidinyl)-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-yl]-, 1,1-dimethylethyl ester
CAS No.1798792-44-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACUJJF772 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUJJF772 route product structure diagram
    ACUJJF7721798792-44-5
Inquiry

2. ACUJJF772 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUJJF772 route product structure diagram
    ACUJJF7721798792-44-5
Inquiry

Comments (0)